Study guide
6.5 ICANS: Assessment, ICE Scoring & Clinical Management
Transplantation and Cellular Therapy Certified Nurse TCTCN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy
2 Chapter 2: Foundations of Transplantation & Cellular Biology
2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum
3 Chapter 3: Product Collection, Processing & Infusion Procedures
3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking
4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease
4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes
5 Chapter 5: Post-Transplant Infections & Supportive Care
5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition
6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS
6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy
7 Chapter 7: Chronic GVHD & Long-Term Survivorship
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment
8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards
8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
6.5 ICANS: Assessment, ICE Scoring & Clinical Management
Key Takeaways Explain This Topic AI
ICANS reflects immune/endothelial neurotoxicity and may occur with, after, or without CRS; immediately evaluate metabolic, infectious, medication, seizure, vascular and structural mimics.
Handwriting change, aphasia, inattention, tremor or cognitive slowing can be early warnings, but no single symptom is universally earliest; compare with baseline.
The 10-point ICE tool scores orientation 4, naming 3, command following 1, writing 1, and counting backward from 100 by tens 1.
ASTCT grade is the worst attributable finding across ICE, consciousness, seizure, motor weakness and elevated ICP/edema; focal/local edema is grade 3 and diffuse edema or specified critical signs are grade 4.
Isolated ICANS is not treated with tocilizumab alone; use product/protocol-directed neurologic care and corticosteroids when indicated, while tocilizumab remains appropriate for concurrent CRS.
Last updated: September 2026
ICANS: Assessment, ICE Scoring & Clinical Management
Quick Clinical Summary: Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is the second most common acute toxicity following CAR T-cell infusion. Typically emerging several days after CRS onset (median Day +4 to +10), ICANS is characterized by cognitive slowing, expressive dysphasia/aphasia, dysgraphia, tremors, lethargy, seizures, and in severe cases, life-threatening diffuse cerebral edema. Bedside assessment relies on the standardized 10-point Immune Effector Cell Encephalopathy (ICE) scoring tool and daily handwriting analysis. First-line therapy for isolated ICANS is Dexamethasone ; Tocilizumab is NOT recommended for isolated ICANS because it does not cross the blood-brain barrier and can paradoxically increase central nervous system IL-6 concentrations.
1. Pathophysiology of ICANS & Neurovascular Unit Disruption
ICANS develops through a complex cascade of systemic endothelial activation, microvascular compromise, and localized central nervous system (CNS) inflammation: ICANS PATHOPHYSIOLOGY CASCADE
- [ Severe Systemic CRS / Cytokine Surge (IL-6, IL-1, TNF-alpha, IFN-gamma) ]
- │
- ▼
- [ Activation of Brain Microvascular Endothelial Cells & Pericytes ]
- │
- ▼
- [ Loss of Tight Junctions (Claudin-5, ZO-1) -> Blood-Brain Barrier Breakdown ]
- │
- ▼
- ┌────────────────────────────────────────────────────────────────────────┐
- │ • Influx of CAR T-Cells & Host Monocytes into Cerebrospinal Fluid (CSF)│
- │ • Microglial Hyperactivation & Astrocyte End-Foot Swelling │
- │ • Excitotoxicity: Elevated Glutamate & Quinolinic Acid │
- │ • Localized Secretion of IL-1beta, IL-6, IFN-gamma, MCP-1 │
- └────────────────────────────────────────────────────────────────────────┘
- │
- ▼
- [ Neurotoxicity: Dysphasia -> Confusion -> Seizures -> Elevated ICP -> Coma ]
- Molecular Mechanisms of Neurovascular Injury
Endothelial Activation & Pericyte Stress: High systemic concentrations of pro-inflammatory cytokines (IFN-gamma, TNF-alpha, IL-6, IL-1beta) and high Angiopoietin-2 (Ang-2) to Angiopoietin-1 (Ang-1) ratios activate the cerebral microvasculature. Pericytes surrounding brain capillaries experience shear stress and detach.
Blood-Brain Barrier (BBB) Disruption: Endothelial tight junction proteins ( claudin-5 , occludin , zonula occludens-1 [ZO-1] ) are degraded, dramatically increasing BBB permeability. High-molecular-weight proteins and systemic cytokines flood into the cerebral parenchyma and cerebrospinal fluid (CSF).
Transmigration of Immune Effector Cells: Activated CAR T-cells and host CD14+ monocytes migrate across the compromised BBB into the CSF and brain parenchyma.
Microglial Activation & Excitotoxicity: Intracranial monocytes and microglia become hyperactivated, secreting massive amounts of IL-1beta, IL-6, and neurotoxic metabolites—including quinolinic acid (an NMDA receptor agonist) and glutamate —provoking neuronal hyperexcitability, epileptic seizures, astrocyte swelling, and vasogenic/cytotoxic cerebral edema.
2. Clinical Presentation & The Stereotypic Spectrum of Neurotoxicity
ICANS exhibits a highly characteristic, progressive clinical course. Recognizing the subtle early herald signs is vital for preventing catastrophic progression: PROGRESSIVE SPECTRUM OF ICANS
- [ Early Herald Signs ] ──> Dysgraphia (Handwriting deterioration)
- Expressive Dysphasia (Word-finding difficulty)
- Fine motor tremor, cognitive slowing
- │
- ▼
- [ Moderate Toxicity ] ──> Global Confusion, Disorientation
- Severe Aphasia (Muteness / Inability to speak)
- Lethargy, Apraxia, Agitation
- │
- ▼
- [ Severe / Critical ] ──> Seizures (Convulsive or Non-Convulsive)
- Motor Paresis / Hemiplegia
- Deep Stupor / Coma
- Diffuse Cerebral Edema / Raised ICP / Herniation
- Clinical Manifestations by Domain
Dysgraphia (useful early warning): A change from baseline handwriting may reveal language, attention, tremor, or motor-planning dysfunction and should trigger a complete ICE/neurologic assessment. It is not universally the first or most sensitive sign.
Expressive Dysphasia / Aphasia: Patients experience word-finding difficulty, paraphasic errors, hesitancy, and progressive expressive dysphasia. Receptive language (comprehension) often remains intact initially while expressive ability deteriorates into complete muteness.
Cognitive & Attention Deficits: Mental slowing, inability to perform serial calculations (serial 7s), retrograde amnesia, disorientation to time and place.
Motor & Movement Abnormalities: Action tremors of the upper extremities, myoclonus, ataxia, asterixis, and facial weakness.
Seizures & Status Epilepticus: Focal motor seizures or generalized tonic-clonic convulsions. Critically, patients may experience non-convulsive status epilepticus (NCSE) , manifesting solely as prolonged unexplained obtundation or catatonia without overt motor jerking.
Elevated Intracranial Pressure (ICP) & Cerebral Edema: Diffuse brain swelling, papilledema, sixth cranial nerve palsy, Cushing's triad (bradycardia, widened pulse pressure / severe hypertension, irregular respirations), and fatal uncal or tonsillar herniation.
3. Standardized Neurologic Assessment: ICE
The adult/adolescent ICE score totals 10 points: orientation to year, month, city and hospital (4); naming three objects (3); following a command (1); writing a standard sentence (1); and counting backward from 100 by tens (1). Establish a baseline and repeat at the product/program interval. Language, vision, hearing, motor, literacy or developmental barriers must be documented and accommodated without silently changing the standardized task. For children younger than 12, use the age-appropriate CAPD/Ped-ICE approach under the program protocol.
4. ASTCT ICANS Grading
Overall grade is the most severe finding not attributable to another cause:
- Domain Grade 1 Grade 2 Grade 3 Grade 4
- ICE 7–9 3–6 0–2 0 because patient is unarousable/unable to perform
Consciousness Awakens spontaneously Awakens to voice Awakens to tactile stimulus Unarousable or needs vigorous/repetitive tactile stimulation; stupor/coma
Seizure None None Any resolving clinical seizure, or nonconvulsive seizure resolving with intervention Prolonged life-threatening seizure over 5 minutes, or repetitive seizures without return to baseline
Motor None None None Deep focal weakness such as hemiparesis/paraparesis
ICP/edema None None Focal/local edema on neuroimaging Diffuse edema, decorticate/decerebrate posturing, cranial nerve VI palsy, papilledema, or Cushing triad
An awake patient with global aphasia and ICE 0 may be grade 3; ICE 0 in an unarousable patient is grade 4. Tremor/myoclonus and intracranial hemorrhage may require care but do not themselves set the ICANS grade.
5. Diagnostic Workup
Repeat neurologic/ICE assessment, review medications and sedation, and check glucose, electrolytes, organ function, oxygenation, infection and concurrent CRS. CT is selected urgently for hemorrhage, focal deficit, trauma, mass effect or severe decline; MRI can characterize other pathology when safe. Use EEG for seizure or unexplained/fluctuating obtundation. Lumbar puncture is selective and depends on pressure concern, platelets/coagulation, infection differential and stability; it is not a routine test for every mild score change.
6. Product- and Protocol-Directed Management
Protect airway, aspiration/fall safety and seizure safety; involve neurology/critical care by severity. Corticosteroid choice, dose, interval and taper follow the product/center pathway and response. Seizure prophylaxis with levetiracetam is used by some products/programs or high-risk pathways, not universally, and treatment of an active seizure follows emergency protocol. Tocilizumab has limited CNS benefit and is not isolated-ICANS monotherapy; give it when concurrent CRS independently warrants it.
For severe ICANS, escalate to ICU airway/EEG management and specialist-directed therapy. Focal edema sets at least grade 3; diffuse edema or critical ICP signs set grade 4 and require neurocritical care. Head positioning, hyperosmolar therapy, ventilation targets and rescue immunomodulation are individualized—fixed sodium targets, mannitol doses or anakinra schedules are not ASTCT grading requirements.